Melanovus Oncology will maintain a small core staff of experienced professionals, and will out-source the majority of its work to minimize unnecessary overhead expenses. This approach ensures operational efficiency, and allows the company to maximize the value of each research dollar. The company either has or has direct access to the necessary business expertise and scientific support necessary to successfully commercialize its products.

The company is focused on completing its few remaining IND-enabling studies, filing its first IND, manufacturing and beginning a Phase I trial for its lead compound. Opportunities exist for collaboration or partnerships on a broad range of activities, including research, clinical development, commercialization and manufacturing.

Melanovus Oncology employs a capital efficient model and will maintain a small core staff of experienced professionals. Highly qualified and experienced contract research and manufacturing partners will perform the majority of this work to minimize overhead expenses. Our goal is to achieve operational efficiency, and to maximize the value of each research dollar. As a virtual entity, the company either has direct access to the necessary business, scientific, and regulatory expertise necessary to successfully commercialize its products.